For 100 subjects with incomplete response to adequate treatment with clozapine, the primary objective is to determine if risperidone augmentation of clozapine is superior to augmentation with placebo, using the outcome measure of total PANSS score
Additional outcome measures will be: proportion of subjects with a 20% or greater reduction in PANSS total score, CGI severity score, CGI improvement score and SOFAS score.
To assess the safety of risperidone augmentation, severity of extrapyramidal side effects, metabolic measures, and general side effects will be studied. Hematological monitoring will be carried out.
(and 2 more...)
18 Years to 65 Years (Adult)
January 6, 2006
May 8, 2006
UBC Hospital Vancouver, British Columbia, Canada
† Study has passed its completion date and status has not been verified in more than two years.